Background Despite clearly improved clinical outcomes for prophylaxis compared to on-
demand therapy, on average only 56% of patients diagnosed with severe hemophilia …

Objective To assess patient preferences for benefits and risks in hemophilia A treatment.
Methods A systematic literature search and pretest interviews were conducted to determine …

Treatment preferences of haemophilia patients with inhibitors have not been well
documented. This study sought to identify treatment attributes that patients/caregivers …

Background Current treatments for hemophilia A in Canada include on-demand treatment
as bleeds occur and regular intravenous prophylactic factor VIII (FVIII) infusions. The …

Introduction New longer-acting factor products will potentially allow for less frequent infusion
in prophylactic treatment of hemophilia. However, the role of administration frequency …

Introduction Clinical trials have shown promising results for extended half‐life factor VIII
concentrates but little is known about individuals' valuation of haemophilia treatment …

The safety and efficacy of treatment options for patients with haemophilia have significantly
improved over the last two decades, particularly with greater utilization of prophylactic …

Little is known about the relative importance of factor VIII (FVIII) treatment attributes to
haemophilia A patients and their willingness to accept trade‐offs among these attributes. To …

Background The clinical benefits of prophylaxis in patients with hemophilia are well‐
established and include the following: reduced bleeding episodes, prevention of joint …

Background: Hemophilia is an inherited condition, requiring lifelong, expensive treatment
driven primarily by the cost of medications. Initiating prophylaxis treatment with factors VIII …